Trial Profile

A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Datopotamab deruxtecan (Primary) ; Durvalumab (Primary) ; Carboplatin; Gemcitabine; Paclitaxel; Pembrolizumab
Indications Male breast cancer; Triple negative breast cancer
Focus Registrational; Therapeutic Use
Acronyms TROPION-Breast05
Sponsors AstraZeneca

29 Apr 2025 Planned End Date changed from 23 Apr 2029 to 26 Mar 2031.
29 Apr 2025 Planned primary completion date changed from 1 Sep 2026 to 1 Dec 2026.
23 Jan 2024 Planned End Date changed from 13 Apr 2029 to 23 Apr 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com